Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEHP.L Share News (EHP)

  • There is currently no data for EHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Winners & Losers: BG Down 5%, CSR Up 5%; Mediazest Drops 21%

Mon, 09th Sep 2013 11:37

LONDON (Alliance News) - The following stocks are the leading risers and fallers on the main London indices midday Monday.

-------

FTSE 100 - Winners

Fresnillo, up 3.2%, are the biggest winners on the blue-chip index. Following a poor performace on Friday, the majority of the mining sector constituents are winners, lead by Fresnillo, which is rebounding after being the biggest loser on the index on Friday.

Rio Tinto, up 1.3%. Despite the mining company expecting medium-term prices to drift lower, Macquarie believes that demand is still growing. The brokerage is positive as management targets sustainable iron-ore cost reductions of USD240 million. At the same time, Rio is applying focus on maximising revenue through technical marketing and quality-control efforts to further support margins. Macquarie is still upbeat about the news that the company made its first shipment of iron ore from its expanded port, rail and mine operations in Australia, as part of its plan to increase the capacity of its iron-ore operations there to 290 million tonnes a year. As a result, Macquarie has maintained an Outperform recommendation, increasing its price target by approximately 2.6% to 4,100 pence.

EasyJet, up 0.7%, and TUI Travel, up 0.9%, continue to rebound following last weeks profit warning from Ryanair that triggered a dramatic fall in share prices for the majority of airline companies.

-------

FTSE 100 - Losers

BG Group, down 4.9%. The oil and gas explorer is by far the biggest faller on the FTSE250 after it announced that delays in projects in Egypt and Norway will hit production in 2014. In an operational update, the oil and gas company said the on-going political and social instability in Egypt means phase 9a of its West Delta Deep Marine project had suffered delay and will now start later than expected in 2014, as long as there aren't further delays. The company also said that first production from the Knarr project in Norway is likely to be delayed by approximately four months into the second half of 2014. BG also announced that it will continue to operate fewer rigs in the US, reducing output there.

Associated British Foods, down 2.1%. The British multinational food processing and retail company said revenues and operating profits for the 52 weeks to September 14 are expected to be ahead of expectations in its retail, agriculture and grocery brands, with sales at Primark for the full year expected to be 22% ahead of last year. However, with EU sugar prices falling fast, the food division is under pressure, and Investec Securities expects to downgrade forecasts for 2014. Investec currently has a Hold rating on the stock, with the price target under review.

-------

FTSE 250 - Winners

CSR, up 5.4%, is the biggest gainers on the FTSE 250. Liberum is encouraged by the hidden value of CSR's highly saleable emerging technologies. Liberum believes that 2014 could see CSR's core business grow substantially faster than in 2013, with the release of multiple new products at the same time. Liberum believes that CSR is trading cheaply, at a discount to its peers, and therefore upgrades the company to Buy from Hold, raising the target price to 550p from 540p.

LondonMetric Property, up 1.8%. The real estate investment trust is one of the biggest winners on the FTSE 250 after it reported that it had acquired distribution warehouses in Northamptonshire and Leicester for GBP23.1 million.

DS Smith, up 1.4%, continues to do well following last week's interim management statement for the three month period to July 31. It has said the current year has started well and in line with its plans, driven by a good performance throughout the group and continued strong delivery of the previously announced synergies from the acquisition of SCA Packaging.

-------

FTSE 250 - Losers

Bwin.party, down 1.4%. Having been one of the big winners on Friday following the announcement that the digital entertainment company's new poker website going live, the company have fallen back to a position similar to levels before the announcement.

-------

AIM - Winners

African Mining & Exploration, up 27%. The mining company has seen a jump in shares prices after it said it has entered into an agreement to acquire an 80% interest in Matilda Minerals Limitada, a privately owned Mozambican heavy mineral sands explorer, for cash and shares.

Richland Resources is up 20% after it announced that pretax losses narrowed in its first half despite illegal miners affecting the company's operations in Tanzania during the period. The precious gemstone exploration and production company said pretax losses narrowed to USD551,000 from USD719,000 for the six months ended June 30. The company managed to increase production levels 28%, to 1.54 million carats from 1.21 million carats the previous year and recovered higher average grades of 93 carats per tonne compared to 61 carats per tonne during the period. The company also lowered administrative costs and operating costs.

Futura Medical, up 17%. The medical company's shares have increased after it moved a step closer to being able to market its CSD500 condom in Europe. It said it got a positive opinion on all aspects of the dossier it submitted to regulators earlier in the year.

Toumaz, up 12%. The UK semiconductor company has teamed up with Spotify to support the new Spotify Connect service on its dual-band connected audio module for audio devices like wireless speakers, AV receivers and internet radios.

Forbidden Technologies is up 8.9% after the company said that it was integrating with Windows Azure Media Services to promote cloud-video work-flows at the 2013 International Broadcasting Convention in Amsterdam. The cloud-video editing company's ForScene service will be shown working with Windows Azure Media Services to edit footage remotely. It said that this near-time clipping of live footage for global video-on-demand deliver would be particularly interesting for sports-rights holders.

Telit Communications, up 8.7%, posted big increases in pretax profits and revenues for the six months ended June 30, as it said it remains confident in meeting full-year expectations after continued investments and acquisitions. The wireless communications company, specialising in direct machine-to-machine connections between devices, had a pretax profit of USD5.6 million, up from USD2.71 million in the previous year. The company's performance was boosted by continued investment in sales and marketing and the recent acquisition of CrossBridge Solutions Inc.

-------

AIM - Losers

Mediazest, down 21%. Shares in the media agency dropped following poor full-year results. The company said that it had endured a disappointing year ended March 31, with turnover falling short and widening losses as a large project was rescheduled and long standing client HMV went into administration. The group posted a pretax loss of GBP551,000, widened from GBP424,000 in the previous year.

Brady, down 17%. The provider of risk management and trading software for global commodity markets has lowered its full year revenue forecast to GBP31.0 million from GBP35.5 million as a result of the complexity and size of upcoming contracts.

EpiStem Holdings, down 15%. The biotechnology company said its talks with US medical company Becton Dickinson, for the expansion of its supply and distribution agreement failed, and that its supply and distribution agreement entered into in August 2012 has now been terminated.

-------

By James Kemp; jameskemp@alliancenews.com

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
7 Dec 2012 15:22

Epistem to raise 4.3m pounds via placing

Epistem, a biotechnology and personalised medicine company is to raise 4.3m pounds before expenses through a placing of approximately 793.4m shares at 545p a share. The new ordinary shares, which represent 8.9% of Epistem's issued share capital have been conditionally placed with existing and new i

Read more
24 Oct 2012 15:32

Investec invests in Epistem

Investec Asset Management has taken a 7.05 per cent stake in Epistem, a biotech firm working in the area of personalised medicine. Over the past three months the loss-making AIM-listed company, Epistem, has shot up approximately 50%. Earlier this month it reported steady full-year results, while d

Read more
16 Oct 2012 08:07

Epistem delivers steady performance

Biotechnology firm Epistem has delivered steady full-year results, while also accelerating investment in a number of its core development programmes. Total sales of £5.6m (2011: £5.8m) were driven by a solid performance by Contract Research Services and strong growth in its Personalised Medicine d

Read more
6 Aug 2012 08:59

Epistem secures contract for TB test

EpiStem, the pre-clinical drugs test firm, has reported that full year trading has been broadly in-line with market forecasts. The firm also said it has reached agreement with US firm Becton Dickinson for the supply and distribution of its Mycobacterium tuberculosis (TB) test on a global basis usin

Read more
5 Jul 2012 10:42

Small caps round-up: Epistem, Stadium Group, Trading Emissions

Biotechnology firm Epistem Hldings said it had received the go-ahead to sells its new tuberculosis product in EEA member state markets. The firm said its Genedrive units provided a major advance in next generation molecular diagnostic testing. Epistem is now preparing regulatory submissions for Indi

Read more
11 Oct 2011 08:44

Big things expected of EpiStem's Genedrive device

Epistem, the biotechnology company specialising in diagnostic aids for the treatment of cancer and gastrointestinal diseases, continued on its steady growth path last year. Revenue in the year to June 30th edged up to £5.75m from £5.74m the year before, while profit on ordinary activities before ta

Read more
29 Mar 2011 13:23

Epistem sees solid growth

Adult stem cell specialist Epistem scraped into profit in the first half of its financial year. The company, which made its maiden full year profit last year, saw profit before tax in the six months to the end of December rise to £0.1m from £5,000 in the corresponding period of 2009. Revenue rose

Read more
5 Oct 2010 13:28

Maiden pre-tax profit for Epistem

UK biotech company, Epistem, celebrates the full year results with a maiden pre-tax profit since becoming an AIM-listed company in 2007. The group has swung to a pre-tax profit of £0.35m, from last year's loss of £0.67m. Revenues rose 45% to £5.7m, from £4.0m previously, as sales rose across all di

Read more
29 Jul 2010 14:16

Small caps: Titon, Utd Drug, Vernalis...

Blinds specialist Titon's revenues for the 3 months to June were 19% higher than the corresponding period last year, with UK sales 15% higher and the rest of the world 37% higher. Growth in the UK came from higher sales of mechanical ventilation systems. There were also increased sales volumes in

Read more
29 Jul 2010 07:38

Epistem FY Trading In line With Market Views, Sees Pretax Profit Up

LONDON (Dow Jones)--Epistem Holdings PLC (EHP.LN), a biotechnology company, said Thursday that trading over the year was in line with market forecasts and the company expects to report growth in year on year after tax profit. -Shares closed Wednesday at 360 pence, valuing the company at GBP28.36

Read more
9 Mar 2010 12:03

EpiStem breaks even as revenue soars

The Novel Therapies division is threatening to steal the show at epithelial stem cells specialist Epistem, as the benefits of its transformational deal with Swiss pharmaceutical giant Novartis kicks in. The UK biotechnology company saw revenue soar 90% in 2009 almost entirely as a result of the co

Read more
9 Nov 2009 11:43

Small caps round-up: Nautical Petroleum, ThirdForce, Allied Gold...

Oil group Nautical Petroleum reported 'significant progress' in its asset portfolio in the year to June 30 and said it expects its assets to rise in value once they move into the execution stage. Pre-tax losses for the year totalled £6.63m, compared with £4.52m the previous year. Shares in e-learn

Read more
12 Oct 2009 17:18

Douglas sure about Shore

Shares in stockbroker Shore Capital have almost tripled in value since April, but non-executive director Barclay Douglas thinks there's more to come. The accountant has spent £92,000 on 250,000 shares at 36.75p each. He now owns 1.25m shares, or half a per cent of the company. Shore received a sho

Read more
6 Oct 2009 11:37

Update: Epistem benefits from raised profile

Drug testing group Epistem moved closer to profit after a research and collaboration deal with the Swiss pharmaceutical giant Novartis helped revenues soar. The firm posted a pre-tax loss of £700,000 in the year to June 30 compared with losses of £1.3m previously, with revenues nearly doubling to £

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.